Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

Table 5 Treatment-related adverse events in HCC patients with Lenvatinib based combination treatment

Adverse Event	Any Grade	Grade I–II	Grade III–V
Any adverse event	68/94.4%	49/68.5%	19/26.3%
Rash	7/9.7%	7/9.7%	0/0.00%
Diarrhea	13/18.1%	10/13.9%	3/4.2%
Anemia	23/31.9%	16/22.2%	7/9.7%
Elevate transaminase	28/38.9%	21/29.2%	7/9.7%
Hypertension	11/15.3%	8/11.1%	3/4.2%
Leukopenia	16/22.2%	12/16.7%	4/5.6%
Thyroid dysfunction	13/18.1%	13/18.1%	0/0.00%
Constipation	4/5.6%	4/5.6%	0/0.00%
Bleeding	8/11.1%	8/11.1%	0/0.00%
Vision loss	1/1.4%	1/1.4%	0/0.00%
Proteinuria	25/34.7%	25/34.7%	0/0.00%
Fever	2/2.8%	2/2.8%	0/0.00%
Fatigue	9/12.5%	9/12.5%	0/0.00%
Hand-foot skin reaction	10/13.9%	10/13.9%	0/0.00%
Decreased appetite	4/5.6%	4/5.6%	0/0.00%
Vomitting	3/4.2%	3/4.2%	0/0.00%
Bloody stools	1/1.4%	1/1.4%	0/0.00%

ISSN: 1475-2867